

## **cPARTICULARS TO APPEAR ON THE OUTER PACKAGE**

### **CARTON**

#### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Johnson's Wormer Plus 230 mg/20 mg Film-coated Tablets for Cats and Kittens

#### **2. STATEMENT OF ACTIVE SUBSTANCES**

Each tablet contains:

Active substances:

20 mg praziquantel  
230 mg pyrantel embonate

#### **3. PACKAGE SIZE**

1 tablet  
2 tablets  
4 tablets

#### **4. TARGET SPECIES**

Cats

#### **5. INDICATIONS**

The product can be used to treat gastrointestinal roundworms and tapeworms commonly found in cats in the UK.

#### **6. ROUTES OF ADMINISTRATION**

Give 1 tablet for every 4 kg bodyweight. For oral administration only.

**Read the package leaflet before use.**

#### **7. WITHDRAWAL PERIODS**

#### **8. EXPIRY DATE**

Exp. {mm/yyyy}

## **9. SPECIAL STORAGE PRECAUTIONS**

Do not store above 25°C. Store in the original packaging. Do not remove tablets from the foil strip until they are required for use. Dispose of any unused half tablets. Do not use after the expiry date stated on the foil strip.

## **10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”**

Read the package leaflet before use.

## **11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

## **12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

## **13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Vetoquinol UK Limited

## **14. MARKETING AUTHORISATION NUMBERS**

Vm 08007/5049

## **15. BATCH NUMBER**

Lot {number}

## **16. OTHER INFORMATION**

### **Do not give this product:**

- If your cat is receiving other medicines containing piperazine. Other deworming products may contain piperazine.
- With other deworming products without veterinary advice.
- If your cat is pregnant.
- To kittens under 6 weeks of age.
- If your cat has a hypersensitivity to any of the ingredients.

Always wash your hands after giving your cat this product.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING**  
**UNITS - BLISTER STRIP**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Johnson's Wormer Plus 230 mg/20 mg Film-coated Tablets for Cats and Kittens

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

230.0 mg      Pyrantel Embonate  
20.0 mg      Praziquantel



**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

Contains 1 tablet.

1  = 4 kg 

## **PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:**

### **PACKAGE LEAFLET**

#### **1. Name of the veterinary medicinal product**

Johnson's Wormer Plus 230 mg/20 mg Film-coated Tablets for Cats and Kittens

#### **2. Composition**

Each tablet contains:

Active substances:

230.0 mg	Pyrantel Embonate
20.0 mg	Praziquantel

Film-coated tablet.

White to yellowish scored coated tablet. The tablet can be divided into equal halves.

#### **3. Target species**

Cats

#### **4. Indications for use**

The product can be used for the treatment of gastrointestinal roundworms and tapeworms: *Toxocara cati*, *Toxascaris leonina*, *Dipylidium caninum*, and *Taenia taeniaeformis*.

#### **5. Contraindications**

##### **Do not give the product:**

- If your cat is receiving other medicines containing piperazine. Other deworming products may contain piperazine.
- With other deworming products without veterinary advice.
- If your cat is pregnant.
- To kittens under 6 weeks of age.
- If your cat has a hypersensitivity to any of the ingredients.

#### **6. Special warnings**

Roundworms and tapeworms are parasites that live in the gut. If left untreated they can cause your cat to become unwell. Treating your cat will reduce the risk of other animals and humans being exposed to worm infections.

Cats may become re-infected with worms following treatment.

Ongoing exposure to worms can occur from eggs in the environment, or by eating insects (including fleas and lice), birds, small rodents or rabbits. The need for and interval between treatments will vary depending on the cat's environment and lifestyle. For guidance specific to your cat, consult a veterinary surgeon or suitably qualified professional.

Fleas serve as intermediate hosts for one common type of tapeworm - *Dipylidium caninum*. Tapeworm infestation is highly likely to re-occur unless control of intermediate hosts such as fleas, mice etc. is undertaken. Flea infestations can be controlled by the use of effective flea control products. Fleas from pets often infest the animal's basket, bedding and regular resting areas such as carpets and soft furnishings which should also be treated with appropriate products.'

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, this may be due to underestimation of body weight or misadministration of the product.

As a precautionary measure to prevent the establishment of *Echinococcus multilocularis* in the UK, it is recommended that all dogs and cats entering the country be treated with praziquantel.

Special precautions for safe use in the target species:

Not intended for use in cats weighing less than 2 kg bodyweight.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the interests of good hygiene, persons administering the tablets directly to a cat, or by adding them to the cat's food, should wash their hands afterwards.

Pregnancy and lactation:

Do not use during pregnancy.

May be used during lactation.

Interaction with other medicinal products and other forms of interaction:

Do not use simultaneously with piperazine compounds, because the specific activities of piperazine (neuromuscular paralysis of the parasites) can inhibit the efficacy of pyrantel (spastic paralysis of the parasites). Other worming products may contain piperazine. Speak to a veterinarian or suitably qualified person if your cat is receiving other medications.

## 7. Adverse events

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Digestive tract disorder <sup>1</sup> (hypersalivation <sup>1</sup> , vomiting <sup>1</sup> ) Neurological disorder <sup>1</sup> (ataxia <sup>1</sup> )
---	--

<sup>1</sup> Mild and short-lived.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

<https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

[adverse.events@vmd.gov.uk](mailto:adverse.events@vmd.gov.uk)

## 8. Dosage for each species, routes and method of administration

For oral use.

Weigh your cat carefully before calculating the dose.

The number of tablets needed to treat your cat depends on your cat's weight. Give 1 tablet for every 4 kg bodyweight. The tablets are scored so that they can be broken in half easily.

Weight of your cat	Dose
Greater than 2 kg up to 4 kg	1 tablet
Greater than 4 kg up to 6 kg	1½ tablets
Greater than 6 kg up to 8 kg	2 tablets

Single oral administration.

The need for and interval between treatments will vary depending on your cat's environment and lifestyle and should be based on professional advice.

If signs of disease persist or appear, consult a veterinary surgeon.

## 9. Advice on correct administration

Give the tablet(s) to your cat by placing directly in the cat's mouth but if necessary hide the medicine in the cat's food.

## 10. Withdrawal periods

Not applicable

## **11. Special storage precautions**

Keep out of the sight and reach of children.

Do not store above 25°C.

Do not remove tablets from strip packaging until required for use.

Any part used tablets should be discarded.

Do not use this veterinary medicinal product after the expiry date which is stated on the foil strip and outer packaging. The expiry date refers to the last day of that month.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product not subject to prescription.

## **14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES**

Vm 08007/5049

The product is available in cartons containing 1, 2 or 4 tablets.

Not all pack sizes may be marketed.

## **15. PID LINK (Do not print heading)**

*[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]*

Find more product information by searching for the 'Product Information Database' on [www.gov.uk](http://www.gov.uk).

## 16. Contact details

### Marketing authorisation holder:

Vetoquinol UK Limited  
Steadings Barn  
Pury Hill Business Park  
Nr. Alderton  
Towcester  
Northamptonshire  
NN12 7LS  
United Kingdom

### Manufacturer responsible for batch release:

KVP Pharma + Veterinär Produkte GmbH  
Projensdorfer Strasse 324  
24106 Kiel, GERMANY  
(for finished product manufactured at KVP)

Or

VETOQUINOL S.A. Magny-Vernois 70200 Lure, FRANCE  
(for finished product manufactured at VETOQUINOL)

### Contact details to report suspected adverse reactions:

Johnson's Veterinary Products Ltd.  
Sutton Coldfield  
West Midlands  
B75 7DF  
Tel: +44 (0)121 378 1684  
Email: [info@johnsons-vet.com](mailto:info@johnsons-vet.com)

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

## 17. Other information

AVM-GSL

To safeguard the health of yourself and your pet, please keep this leaflet and read it before you administer the product to your pet.

*Gavin Hall*  
Approved: 13 January 2026